SWOT Analysis
Strengths: Availability of various reconstruction procedure options such as implant, autologous reconstruction using DIEP or TRAM flap technique suits patient needs.
Weaknesses: High cost associated with autologous reconstruction procedures limits their access. Post-surgery complications associated with implants requires revision surgeries.
Opportunities: Rising breast cancer incidence rates worldwide presents growth prospects. Increasing reimbursement and favourable regulations in developed nations support market growth.
Threats: Strong competition from alternative treatments and lack of reimbursement in developing nations are key challenges.
Key Takeaways
The Global Breast Reconstruction Market Size was valued at US$ 567 million in 2023 and is expected to reach US$ 794 million by 2030, expanding at a CAGR of 2.7% from 2023 to 2030. Rapid growth can be attributed to rising cancer incidence rates globally. The APAC region dominates the market currently due to high cancer burden in China and India. North America is expected to witness lucrative growth owing to advanced medical care and presence of major players in the US.
Regional analysis
The Asia Pacific region currently dominates the global market backed by the rising cancer prevalence in highly populated countries such as China and India. According to International Agency for Research on Cancer, China accounted for over 25% of the global breast cancer cases in 2020. Additionally, improving access to healthcare infrastructures in developing Asian countries is supporting the uptake of breast reconstruction procedures in the region.
Key players operating in the breast reconstruction market are Polytech Health & Aesthetics GmbH, Allergan, Mentor Worldwide LLC (Johnson & Johnson), Sientra Inc., GC Aesthetics, RTI Surgical, Inc., Groupe Sebbin SAS, Integra LifeSciences, and Wanhe. The major players are focusing on new product launches, geographic expansions and mergers and acquisitions to get a larger share of the market.